
MD Anderson at the San Antonio Breast Cancer Symposium



December 10-14, 2019

Henry B. González Convention Center | San Antonio, TX



PRESENTATIONS					
Tuesday, Dec. 10					
2-3:30 p.m.	Workshop: Evolving Opportunities to Personalize Radiation Decisions	Guiding selection of RT approach after lumpectomy	Simona Shaitelman, M.D.	Stars at Night Ballroom 2 - 3rd Level	
3:45-5:15 p.m.	Workshop: Implementation of Genetic Testing in Breast Cancer Patients	Alternative practical models for genetic services in the era of increased demand	Banu Arun, M.D.	Stars at Night Ballroom 2 - 3rd Level	
3:45-5:15 p.m.	Workshop: Conversations on Tough Topics Surrounding Cancer Care Moderated by Susan Rafte	Challenging conversations: The toll on healthcare providers	Sharon Giordano, M.D.	Stars at Night Ballroom 3 & 4 - 3rd Level	
Wednesday, Dec. 11					
8:45-11:15 a.m	General Session 1	Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)	Rashmi Murthy, M.D.	Hall 3	
Thursday, Dec. 12					
7-9 a.m.	Spotlight Session 4	Discussant for Spotlight Session 4 Targeting HER2 and DNA Repair	Jennifer Litton, M.D.	Stars at Night Ballroom 1 & 2 - 3rd Level	
1-2 p.m.	Case Discussion 1		Benjamin Smith, M.D.	Stars at Night Ballroom 1 & 2 - 3rd Level	

3:15-5 p.m.	General Session 4	Investigating genomic and phenotypic evolution of triple-negative breast cancer chemoresistance and metastasis in patient-derived xenografts	Gloria Echeverria, Ph.D.	Hall 3
5-7 p.m.	Spotlight Session 6	Local Regional Therapy/DCIS	Karen Hoffman, M.D.	Hemisfair Ballroom - 3rd Level
5-7 p.m.	Spotlight Session 7	The Science of ER Resistance and Emerging Clinical Strategies	Stacy Moulder, M.D.	Stars at Night Ballroom 2 - 3rd Level
5-7 p.m.	Spotlight Session 7	Discussant for The Science of ER Resistance and Emerging Clinical Strategies	Rachel Layman, M.D.	Stars at Night Ballroom 2 - 3rd Level
		Oll lloar Otratogics		
Friday, Dec. 1	3	Omnour dirategres		
Friday, Dec. 1 9:45-11:30 a.m. (9:45 a.m.)	General Session 5	Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis	W. Fraser Symmans, M.D.	Hall 3
9:45-11:30 a.m.		Residual cancer burden after neoadjuvant therapy and long- term survival outcomes in breast cancer: A multi-center	W. Fraser Symmans, M.D. Henry Kuerer, M.D.	Hall 3

POSTER PRESENTATIONS					
Thursday, Dec. 12					
7-9 a.m.	Poster Session 2	P2-09-04 Reclassification of variant of unknown significance in <i>BRCA1</i> and <i>BRCA2</i> genes based on loss of Heterozigosity assay		Hall 1	
7-9 a.m.	Poster Session 2	P2-11-03: Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer	W. Fraser Symmans, M.D.	Hall 1	
5-7 p.m.	Poster Session 3	P3-11-14: ONC201 synergistically induces cell death in triple-negative breast cancer with CDK 4/6 and MEK inhibition	Bora Lim, M.D.	Hall 1	
Friday, Dec. 13					
7-9 a.m.	Poster Session 4	P4-01-01: Circulating tumor cells detected after neoadjuvant therapy for inflammatory breast cancer are associated with early relapse despite pCR	Anthony Lucci, M.D.	Hall 1	

5-7 p.m.	Poster Session 5	P5-14-03 (presenting on behalf of Arlene Chan first author): Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-Positive early-stage breast cancer: Phase II CONTROL trial.	Carlos Barcenas, M.D.	Hall 1	
5-7 p.m.	Poster Session OT3	OT3-15-02: A randomized, double-blind, placebo- controlled study of 4- hydroxytamoxifen topical gel in women with mammographically dense breasts	Banu Arun, M.D.	Hall 1	
Saturday, Dec. 14					
7-9 a.m.	Poster Session 6	P6-08-06: Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer	Banu Arun, M.D.	Hall 1	
7-9 a.m.	Poster Session 6	P6-08-26: Clinical characteristics of breast cancer patients with ATM mutations	Banu Arun, M.D.	Hall 1	

2019-1254 PR SABCS19